• ≥18 years old;

• Sign on the informed consent;

• Subjects must have histologically confirmed Large B-cell Lymphoma;

• Subjects had been treated with anthracyclines and rituximab(or other CD20-targeted antibodies) and had relapsed, failed to respond, or progressed after at least two lines of therapy including autologous hematopoietic stem cell transplantation(auto-HSCT);

• Subjects have accessible PET-positive lesion and have measurable CT-positive lesion according to Lugano Classification;

• Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1;

• Adequate organ function;

• Adequate vascular access for leukapheresis procedure;

• Subjects who have previously received CD19 targeted therapy must confirm that lymphoma lesions still express CD19;

⁃ Women of childbearing potential must agree to use highly effective methods of contraception for 1 year after the last dose of Relma-cel;

⁃ Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for 1 year after the last dose of Relma-cel.